GenScript ProBio, a global antibody and gene therapy contract development and manufacturing organization (CDMO), has announced 2022 manufacturing expansion plans to meet the increasing demand for commercial cGMP plasmid and viral vector manufacturing to service its cell and gene therapy global clients. 

GenScript ProBio broke ground for the construction of its newest plasmid and viral vector manufacturing facility, a 34,000-square-meter cGMP facility in Zhenjiang, Jiangsu.

GenScript ProBio's new facility will be state-of-the-art, utilizing the latest technology and equipment in viral vector and plasmid manufacturing to scale up its production capacity and deliver end-to-end cell and gene therapy capabilities. The expansion project includes a plasmid center and viral vector center, which will house plasmid and virus manufacturing facilities and manufacturing science and technology (MSAT) laboratories.

The entire facility will be designed in compliance with the cGMP requirements of the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and National Medical Products Administration (NMPA).